Metabolic Syndrome and Menopause: Pathophysiology, Clinical and Diagnostic Significance

Adv Clin Chem. 2015:72:1-75. doi: 10.1016/bs.acc.2015.07.001. Epub 2015 Aug 21.

Abstract

Menopause is a risk factor for cardiometabolic diseases, including metabolic syndrome (MetS), type 2 diabetes, and cardiovascular diseases. MetS is a constellation of interdependent factors such as insulin resistance, abdominal obesity, dyslipidemia, and hypertension. The prevalence of MetS in postmenopause is due to loss of the protective role of estrogens and increased circulating androgens resulting in changes to body fat distribution and development of abdominal obesity. Excessive visceral adipose tissue plays an important role due to synthesis and secretion of bioactive substances such as adipocytokines, proinflammatory cytokines, reactive oxygen species, prothrombotic, and vasoconstrictor factors. MetS may also impact risk assessment of breast cancer, osteoporosis and chronic kidney disease, and quality of life during the menopausal transition. Increased MetS has stimulated the exploration of new laboratory tests for early detection and therapies.

Keywords: Cardiovascular disease; Insulin resistance; Menopause; Metabolic syndrome; Sex hormones.

Publication types

  • Review

MeSH terms

  • Adult
  • Female
  • Humans
  • Menopause*
  • Metabolic Syndrome / diagnosis
  • Metabolic Syndrome / physiopathology*
  • Middle Aged